» Articles » PMID: 20185296

Constitutive HIF-1 Activity in Malignant Melanoma

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2010 Feb 27
PMID 20185296
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

The hypoxia-inducible factor-1 (HIF-1), which consists of the constitutive HIF-1beta and the oxygen-responsive HIF-1alpha subunit, is the master activator of the cellular transcriptional response to hypoxia coordinating gene expression during reduced oxygen tension. Overexpression of HIF-1 and increased transcriptional activity induced by hypoxia are linked to progression of many tumour types such as head and neck cancer, cervical carcinoma, leukaemia and renal cell carcinoma. In this study, we demonstrate that HIF activity is increased in malignant melanoma cells already under normoxic conditions in contrast to other tumour types. HIF-1alpha and -2alpha knockdown by siRNA transfection revealed that this effect is due to constitutive HIF-1alpha expression. Furthermore, the inhibition or activation of reactive oxygen species (ROS) decreased or activated, respectively, HIF-1 activity and HIF-1alpha protein expression. Interestingly, the inhibition of the NFkappaB pathway also reduced the accumulation of HIF-1alpha assuming a context between ROS and NFkappaB, and suggesting that ROS and NFkappaB activity contribute to HIF-1alpha accumulation. In summary, we identified an increased HIF-1alpha protein expression and activity in melanoma under normoxia mediated by ROS and the NFkappaB pathway.

Citing Articles

Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma.

Montico B, Giurato G, Guerrieri R, Colizzi F, Salvati A, Nassa G J Exp Clin Cancer Res. 2025; 44(1):53.

PMID: 39953610 PMC: 11827140. DOI: 10.1186/s13046-025-03289-8.


Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma.

Farah C, Mignion L, Jordan B Int J Mol Sci. 2024; 25(3).

PMID: 38339003 PMC: 10855758. DOI: 10.3390/ijms25031725.


and study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells.

Wawszczyk J, Wolan R, Smolik S, Kapral M Saudi Pharm J. 2023; 31(7):1306-1316.

PMID: 37323921 PMC: 10265481. DOI: 10.1016/j.jsps.2023.05.020.


Dexamethasone and OLT1177 Cooperate in the Reduction of Melanoma Growth by Inhibiting STAT3 Functions.

Dinarello A, Mills T, Tengesdal I, Powers N, Azam T, Dinarello C Cells. 2023; 12(2).

PMID: 36672229 PMC: 9856388. DOI: 10.3390/cells12020294.


BIRC7 is Beneficial for Melanoma Progression and Hypoxic Response.

Xu H, Liu H, Li Z, Xu Q, Lin N, Li X Clin Cosmet Investig Dermatol. 2022; 15:1109-1117.

PMID: 35747741 PMC: 9212797. DOI: 10.2147/CCID.S370969.